Current Treatment Landscape for Moderate to Severe Atopic Dermatitis, With Raj Chovatiya, MD, PhD

A session on the current treatment landscape for atopic dermatitis was presented during the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, with 2 experts in the field of dermatology as presenters: Raj Chovatiya, MD, PhD, and Chih-ho Hong, MD, FRCPC.

Chovatiya, a clinical associate professor at Rosalind Franklin University Chicago Medical School and director of the Center for Medical Dermatology and Immunology Research, highlighted several key takeaways on the biggest news in atopic dermatitis management in 2025. He was asked about the impetus for covering this topic at EADV.

“[This is] a really fun evening symposium where we're getting a chance to dive into atopic dermatitis in general and talk about some of the unmet needs in our disease state, with a focus on what potentially the class of medications that block the OX40 receptor might unlock for us,” Chovatiya explained. “And of course, in this particular program, we're going to get a chance to talk about many different medications that are taking different approaches, and then highlight some of the newer data for rocatinlimab, our OX40 receptor blocker that's the furthest along on clinical development, that are really suggesting that, indeed, we may have another treatment on our hands for patients with moderate to severe atopic dermatitis.”

Chovatiya added that during the session, updates were being presented to contextualize the immunology of what makes a medication make sense for clinicians and for patients using the atopic dermatitis toolbox. Afterward, he discussed his session titled ‘Personalizing the Care of Patients With Atopic Dermatitis and Head and Neck Involvement.’

“I’m also having a chance to give a talk about head and neck atopic dermatitis, a very common and burdensome phenotype of disease itself,” Chovatiya said. “And this one is a bit more medication agnostic, in the sense that what we're really trying to understand is, why the head and neck has such a unique burden. Why is it so challenging to treat and what are some of the circumstances in which this area tends to get worse, even though other parts of the body can get better? [Also] what are some of the therapeutic solutions, particularly in the biologic realm, that can help us to treat our patients?”

Chovatiya added that there can be significant burdens that come with head and neck atopic dermatitis, noting that it really behooves clinicians to go beyond topical therapies to make sure such patients are receiving the appropriate medication choices.

For additional information on this topic and others highlighted during EADV 2025, view our latest coverage of this conference.

Raj Chovatiya has reported serving as an adviser, a consultant, a speaker or an investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CLn Skin Care, Dermavant, Eli Lilly, EMD Serono, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L'Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio and UCB.

References

1. Session: The Current Treatment Landscape for Moderate to Severe AD. Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Sept 17-20, 2025.